Skip to content

Clinical study of astragalus and zedoary granules

Clinical study of astragalus and zedoary granules

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079962
Enrollment
Unknown
Registered
2024-01-17
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-cancerous state and precancerous lesions of the gastric mucosa

Interventions

treatment group:Astragalus and zedoary granules, taken with water, divided into morning and evening, for 6 months.

Sponsors

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 70 years, regardless of gender; (2) Those who meet the diagnostic criteria for patients with pre-cancerous state of the stomach or pre-cancerous lesions of the stomach and are negative for Helicobacter pylori (at least one of the C13 or C14 respiratory tests is required); (4) Those who voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with combined peptic ulcers, pathologically confirmed high-grade intraepithelial neoplasia or suspected malignancy; (2) Those with severe digestive diseases or history of abdominal surgery; (3) Pregnant and lactating women; (4) Those who have a combination of serious heart, lung, hematopoietic system, malignant tumor and other primary diseases, or other systematic serious diseases; (5) Patients with disabilities prescribed by law; (6) Long-term use of NSAID drugs, history of alcoholism; (7) Those who are allergic or have a history of allergy to multiple drugs; (8) Those who have participated in clinical trials of other drugs in the last 4W, or have used preparations such as gastrointestinal fuchsin and folic acid in the last 2 weeks; (9) Those who are prone to lost visits.

Design outcomes

Primary

MeasureTime frame
Pathologic biopsy of gastric mucosa;

Secondary

MeasureTime frame
MeasureYourself Medical Outcome Profile;

Countries

China

Contacts

Public ContactLi Xuejun

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

lixuejun0308@126.com+86 135 1551 2139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026